Nitric oxide is produced by your body to help combat inflammation and when your airway is inflamed, NO is produced in the lungs and exhaled on the breath.

Airway inflammation is a central process in asthma and other lung diseases.

Fractional exhaled Nitric Oxide (FeNO) can be used as a non-invasive biomarker of airway inflammation to help differentiate between allergic and non-allergic asthma, as well as between asthma and other respiratory conditions.

The NObreath® FeNO monitor offers a quick, easy-to-use and non-invasive way to monitor airway inflammation, through breath analysis. With adult, child and ambient profiles, the NObreath® FeNO monitor is the essential tool for asthma.

Benefits of performing FeNO tests include:

- Shows a patient’s response to treatment, enabling the correct prescription of medication and safer/monitored adjustments
- Shows patient compliance to medication
- Aids in identifying patients who do/do not require on-going treatment
  - Aids in differentiating between allergic (eosinophilic) and non-allergic asthma

Dr. Stephen O’Hickey, a Respiratory Consultant at Worcestershire Acute NHS Trust, comments, “We first chose to use the NObreath® because we needed a cost effective and easily portable device for community based clinics. We use the device in peripheral clinics for
monitoring asthma control and to investigate the cause of coughing, where we see around 5-6 patients per clinic in 2 to 3 clinics per week. On the whole it is a quick process, however some patients find it difficult to use, I’m pleased with the small size and portability - FeNO monitoring has been a big development in the management of difficult asthma in peripheral clinics.”

References

3. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: